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Background: To determine whether or not jugular venous reflux (JVR) is associated with structural brain
parenchyma changes in individuals with mild cognitive impairment (MCI) and Alzheimer’s disease (AD).
Methods: 16 AD patients (mean (SD): 81.9 (5.8) years), 33 MCI patients (mean (SD): 81.4 (6.1) years) and 18 healthy
elderly controls (mean (SD): 81.5 (3.4) years) underwent duplex ultrasonography and magnetic resonance imaging
scans to quantify structural brain parenchyma changes. Normalized whole brain (WB), gray matter (GM) and white
matter (WM) volumes were collected, together with CSF volume.
Results: JVR was strongly associated with increased normalized WB (p = 0.014) and GM (p = 0.002) volumes
across all three subject groups. There was a trend towards increased WB and GM volumes, which was
accompanied by decreased CSF volume, in the JVR-positive subjects in both the MCI and AD groups. When
the MCI and AD subjects were aggregated together significant increases were observed in both normalized
WB (p = 0.009) and GM (p = 0.003) volumes for the JVR-positive group. No corresponding increases were observed for
the JVR-positive subjects in the control group. Through receiver operating characteristic analysis of the brain volumetric
data it was possible to discriminate between the JVR-positive and negative AD subjects with reasonable accuracy
(sensitivity = 71.4%; specificity = 88.9%; p = 0.007).
Conclusions: JVR is associated with intracranial structural changes in MCI and AD patients, which result in increased
WB and GM volumes. The neuropathology of this unexpected and counterintuitive finding requires further
investigation, but may suggest that JVR retrogradely transmits venous hypertension into the brain and leads to brain
tissues swelling due to vasogenic edema.
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volumeBackground
Alzheimer's disease (AD), the most common form of de-
mentia in the elderly, is thought to be caused by an imbal-
ance between amyloid-β (Aβ) production and clearance
leading to Aβ accumulation in the central nervous system
(CNS), which causes neuronal damage and death, mani-
festing as progressive clinical dementia [1-3]. It has been
shown that patients with AD have 30% slower clearance* Correspondence: c.b.beggs@bradford.ac.uk
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reproduction in any medium, provided the orof Aβ [1]. One of the possible etiologies of decreased Aβ
clearance is impaired cerebrospinal fluid (CSF) flow [1,4].
When venous hypertension occurs in the superior sagittal
sinus, CSF absorption is also impaired, leading to altered
CSF outflow [5-7]. Jugular venous reflux (JVR) character-
ized by a retrograde flow in internal jugular veins (IJVs)
during Valsalva-like manoeuvres (VM) or spontaneously,
is found more frequently in the elderly [8,9]. Studies have
shown that JVR can retrogradely transmit hypertension
into the cerebral venous system and that it is associated
with white matter (WM) abnormalities in the elderly
[10,11]. Consequently, there is reason to believe that JVRtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fluence the clearance of Aβ. Given this, we hypothesized
that JVR might be associated with mild cognitive impair-
ment (MCI) and AD, and that this association might
manifest itself in structural changes in the brain paren-
chyma. To this end, we undertook a case-controlled study
to explore the issue by evaluating the relationship between
JVR and global and tissue specific brain parenchyma volu-
metric parameters. Volumetric analysis of brain paren-
chyma structures measured on serial magnetic resonance
imaging (MRI) scans has been shown to provide an ob-
jective and quantitative method for examining neuro-
pathological changes associated with AD [12-18].
Methods
Patient population
Between December 2008 and April 2010, Taiwanese
residents consecutively admitted to a memory clinic at
Taipei Veterans General Hospital, Taiwan due to sub-
jective memory complaints were assessed for inclusion
in this study. Neurologists performed clinical and neuro-
logic evaluations of all participants. Standard neuro-
psychological assessments, including the Mini-Mental
State Examination (MMSE) and Clinical Dementia Rat-
ing (CDR) scale were used.
Subjects eligible for participation in the current study
were 55 years of age or older, had a CDR score ≤1 (as an
assurance that they could cooperate during the Valsalva
manoeuvre for JVR detection), and were willing to receive
brain MRI and neck duplex ultrasonography. Exclusion
criteria for all subjects were a past history of stroke, ische-
mic heart disease, congestive heart disease, valvular heart
disease, cardiac arrhythmia, pulmonary diseases, or malig-
nancy, and having brain MRI of insufficient quality for
performing quantitative brain volumetric analysis. The
inclusion/exclusion criteria, clinical evaluation, and
duplex ultrasonography and MRI protocols and rating
method, were pre-defined before the study.
Vascular risk factors were defined according to inter-
national guidelines and prospectively identified using all
available information including medical charts, laboratory
results, patient interviews, and neurological examinations.
Hypertension was defined as a history of hypertension,
use of antihypertensive medications, or a measured blood
pressure consistently >140/90 mmHg. Hyperlipidemia was
defined as a cholesterol level >200 mg/dL, low density
lipoprotein >150 mg/dL, triglyceride level >150 mg/dL, or
history of hyperlipidemia. Diabetes was defined as a his-
tory of diabetes, use of medications for diabetes, or an ele-
vated fasting blood glucose >126 mg/dL.
Subjects were classified in AD, mild cognitive impair-
ment (MCI) or control groups according to the criteria
of National Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer's Disease and RelatedDisorders Association [19], and by Petersen et al.’s study
revised by the Stockholm consensus group [20,21]. The
hospital’s Institutional Review Board approved the study
and each included participant or his/her caregiver pro-
vided informed consent.Color-coded duplex ultrasonography for JVR
determination
Neck color-coded duplex sonography was performed in
all subjects with a 7-MHz linear transducer (iU22;
Philips, New York, NY, USA) by the same technician,
who was blinded to subjects’ characteristics. On examin-
ation, subjects were in a head-straight, flat supine position
after a quiet 10 min rest. The IJV was initially insonated
longitudinally and thoroughly from the proximal part of
the neck base rostrally to the distal part at the subman-
dibular level in order to detect any possible spontaneous
JVR at baseline. Then, the VM was performed by
forcible expiration from subject’s mouth into a flexible
rubber tube connected to a manometer. Subjects were
asked to reach 40 mmHg Valsalva pressure and main-
tain it for at least 10 seconds. During the VM, the dis-
tal margin of the window of the color signal was placed
at the tip of the flow divider of the internal carotid artery.
The color box was adjusted to include the entire lumen of
the IJV; if retrograde color appeared in the center of the
lumen, the retrograde flow would then be confirmed
by Doppler spectrum. JVR was determined when the
retrograde-flow color in the center of the lumen and
the Doppler-flow waveform demonstrated reversal of
flow for more than 0.5 seconds [9-11]. JVR was deemed to
have occurred if it could be detected spontaneously at
baseline or during the VM. The subjects were classified
according to JVR status: subjects with no JVR on both
sides were classified as JVR-negative, and subjects with
JVR detected on either or both sides during VM, or spon-
taneously, were graded as being JVR-positive.MRI acquisition
All study participants were scanned on 1.5 T MRI
(Excite II; GE Medical Systems, Milwaukee, WI). MRI
brain sequences included axial two dimensional (2D)
T2-weighted imaging (WI) and fluid-attenuated inver-
sion recovery (FLAIR), and three dimensional (3D)
T1 spoil gradient echo (SPGR) pulse sequences. The
images were acquired with the following sequence pa-
rameters: for 3D T1 the repetition time (TR) was
8.545 ms, echo time (TE) 1.844 ms, inversion time
(TI) 400 ms, flip angle (FA) 15, slice thickness 1.5 mm,
field of view (FOV) 260×260 mm and matrix 256×256; for
T2 the TR was 3,700 ms, TE 102 ms, echo train length
19, slice thickness 3 mm, FOV 240×240 mm and
matrix 256×256; for FLAIR: TR 9,000 ms, TE 120 ms,
Table 1 Demographic and clinical characteristics of study
cohort grouped by clinical disease status
Variable Controls MCI AD Significance
p value
Number of subjects,
n (%)
18 (26.9) 33 (49.3) 16 (23.9) n.a.
Female gender,
n (%)
4 (22.2) 13 (39.4) 8 (50.0) 0.233*
Age in years,
mean (SD)
81.5 (3.4) 81.4 (6.1) 81.9 (5.8) 0.946
Years of education,
mean (SD)
13.5 (1.9) 11.3 (4.1) 10.0 (3.8) 0.018
JVR positive, n (%) 13 (72.2) 24 (72.7) 7 (43.8) 0.106*
MMSE, mean (SD) 28.0 (1.5) 26.2 (1.9) 20.3 (2.8) <0.001
Hypertension, n (%) 12 (66.7) 17 (51.5) 11 (68.8) 0.401*
Diabetes, n (%) 3 (16.7) 6 (18.2) 3 (18.8) 0.986*
Hyperlipidemia,
n (%)
3 (16.7) 3 (0.9) 7 (43.8) 0.015*
Smoking, n (%) 1 (0.6) 1 (3.0) 0 (0.0) 0.637*
Normalized WB
volume, mean (SD)
1342.1 (50.6) 1308.9 (62.1) 1291.6 (51.3) 0.034
Normalized GM
volume, mean (SD)
728.1 (35.7) 715.3 (44.1) 698.0 (37.5) 0.104
Normalized WM
volume, mean (SD)
614.1 (27.7) 593.6 (34.3) 593.6 (29.7) 0.072
CSF volume 383.4 (47.0) 358.1 (60.1) 372.7 (72.9) 0.346
MCIMild cognitive impairment, AD Alzheimer’s disease, JVR Jugular venous reflux,
MMSEMini-mental state examination,WBWhole brain, GM Gray matter,WMWhite
matter, CSF Cerebrospinal fluid.
All volumes are expressed in milliliters.
ANOVA One-way analysis of variance, n.a. Not applicable, SD Standard deviation,
n Number, % - Percentage.
p value determined by one-way ANOVA unless otherwise stated.
*p value determined using chi square test.
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and matrix 256×256.
MRI analysis
The MRI volumetric analyses were blinded to the sub-
jects’ demographic and clinical characteristics. For brain
extraction and tissue segmentation into normalized
whole brain (WB), gray matter (GM), WM, and CSF vol-
umes, the SIENAX cross-sectional software tool was
used (version 2.6), with corrections for T1-hypointensity
misclassification using an in-house developed in-painting
program, as previously described [22].
Statistical analysis
Statistical analysis was undertaken using a combination of
the Statistical Package for Social Sciences (SPSS, IBM,
Armonk, New York, USA) and in-house algorithms written
in Matlab (Mathworks, Natick, Mass) with the aim of evalu-
ating the impact of JVR on the respective MRI variables.
Parametric (one-way ANOVA) and non-parametric (2-
tailed Mann Whitney U-test, chi square test) univariate
analyses were performed on the respective study cohorts
to identify significant differences between the various
groups. Values of p < 0.05 were considered statistically
significant. For the purposes of this analysis, individuals
were simply classified according to clinical disease classi-
fication (i.e. controls, MCI and AD) and whether or not
they were JVR-positive.
In order to calculate sensitivity and specificity scores
related with any structural MRI changes that might be
associated with JVR, we also performed receiver operat-
ing characteristic (ROC) analysis using a bespoke Matlab
algorithm [23]. So as to maximize the discrimination
characteristics of the ROC analysis, principal component
analysis (PCA) was used to combine MRI variables iden-
tified as being influential by the univariate analysis. The
ROC analysis was then performed using the first princi-
pal component (i.e. the principal component responsible
for most variance in the data).
Results
Subjects
Eighty-four subjects [57–93 years of age; mean (SD):
79.77 (7.41) years; 33 women; 31 control subjects, 33
MCI subjects, and 20 AD subjects] with eligible brain
MRI scans were enrolled according to our criteria. To
match age and gender in each disease group, 67 subjects
[64–93 years of age; mean (SD): 81.5 (5.3) years; 25
women] were enrolled for further analysis. This study
population comprised; 18 control subjects [mean (SD):
81.5 (3.4) years; 4 women], 33 MCI subjects [mean (SD):
81.4 (6.1) years; 13 women], and 16 AD subjects [mean
(SD): 81.9 (5.8) years; 8 women] (Table 1). All the AD
patients met the diagnostic criteria for AD and CDR = 1;and all MCI patients met the diagnostic criteria for MCI
and had a CDR = 0.5. Twenty-nine subjects (43.3%) had
right-sided JVR (all detected during VM) and 32 subjects
(47.7%) had left-sided JVR (10 detected spontaneously at
rest and 22 detected during VM). There were 22 sub-
jects (32.8%) with bilateral JVR; among them, 5 had
unilateral spontaneous JVR at rest with contralateral
VM-induced JVR and 17 had bilateral VM-induced JVR.
Twenty-three subjects (34.3%) presented with JVR on nei-
ther side. In the control group, 13 subjects (72.2%) were
JVR-positive, and in the MCI group, 24 subjects (72.7%)
JVR-positive. By comparison, in the AD group only 43.8%
of the subjects (7 subjects) were JVR-positive.
Demographic and clinical univariate analysis
Table 1 shows the comparisons of clinical characteristics
and MRI variables between control, MCI and AD groups.
From this it can be seen that for all but three of the clin-
ical variables there was no significant difference between
the respective groups. The only exceptions to this were:
the MMSE score, which was significantly lower in the AD
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was on average approximately 3 years less in the MCI and
AD groups (p = 0.018); and hyperlipidemia, which had a
higher incidence in the AD group (p = 0.015). Of the MRI
variables, only normalized WB volume showed a signifi-
cant difference between the three groups, being signifi-
cantly smaller in the AD group (p = 0.034).
Table 2 shows demographic, clinical and MRI character-
istics of the whole study population aggregated together
and grouped according to JVR status (i.e. JVR-positive and
negative). The two JVR-graded groups were closely age-
matched and had similar clinical characteristics, with no
significant differences in sex, education, and disease classi-
fication. However, significantly increased normalized WB
(p = 0.014) and GM (p = 0.002) volumes were observed in
the JVR-positive group. The increase in brain parenchyma
volume in the JVR-positive subjects was matched by a cor-
responding decrease in CSF volume, although this did not
reach significance.Table 2 Demographic and clinical characteristics of study
cohort grouped by JVR status (i.e. positive or negative)
for all groups aggregated together
Variable JVR
negative
JVR
positive
Significance
p value
Number of subjects, n (%) 23 (34.3) 44 (65.7) n.a.
Female gender, n (%) 9 (39.1) 16 (36.4) 0.824*
Age in years, mean (SD) 81.6 (3.3) 81.5 (6.2) 0.740
Years of education,
mean (SD)
11.8 (3.8) 11.5 (3.7) 0.720
Disease classification, n (%) 0.106*
Control 5 (21.7) 13 (29.5)
MCI 9 (39.1) 24 (54.5)
AD 9 (39.1) 7 (15.9)
MMSE, mean (SD) 24.0 (4.1) 26.0 (3.1) 0.065
Hypertension, n (%) 12 (52.2) 28 (63.6) 0.364*
Diabetes, n (%) 6 (26.1) 6 (13.6) 0.207*
Hyperlipidemia, n (%) 5 (21.7) 8 (18.2) 0.727*
Smoking, n (%) 0 (0.0) 2 (4.5) 0.299*
Normalized WB volume,
mean (SD)
1286.6 (58.3) 1327.9 (54.8) 0.014
Normalized GM volume,
mean (SD)
692.6 (41.0) 726.1 (40.0) 0.002
Normalized WM volume,
mean (SD)
594.0 (32.6) 601.8 (32.5) 0.531
CSF volume 380.5 (58.7) 362.0 (60.9) 0.253
MCI Mild cognitive impairment, AD Alzheimer’s disease, JVR Jugular venous
reflux, MMSE Mini-mental state examination, WB Whole brain, GM Gray matter,
WM White matter, CSF Cerebrospinal fluid.
All volumes are expressed in milliliters.
n.a. Not applicable, SD Standard deviation, n Number, % - Percentage.
p value determined by 2-tailed Mann Whitney U-test unless otherwise stated.
*p value determined using chi square test.In order to determine whether or not the increase in
WB and GM volumes was exhibited in all three clinical
groups, we repeated the univariate analysis for each dis-
ease classification group. The results of this analysis are
presented in Table 3, which reveals a trend towards in-
creased WB and GM volumes in the JVR-positive sub-
jects in both the MCI and AD groups, evidenced by
Cohen’s d effect sizes >0.8. When the MCI and AD sub-
jects were aggregated together the univariate analysis
revealed even more significant increases in both nor-
malized WB (p = 0.009) and GM (p = 0.003) volumes
for the JVR-positive group. No corresponding differ-
ence was observed between the JVR-positive and nega-
tive subjects in the control group. Similarly in the
controls, no significant difference in CSF volume was
observed between the JVR-positive and negative groups,
whereas in the MCI and AD subjects there was a trend to-
wards reduced CSF volume.
Separate analysis of the JVR-negative group revealed a
statistically significant difference between the controls
and the MCI and AD subjects for the normalized WB
(p = 0.023) and WM (p = 0.028) volumes, both of which
were greatly reduced in the JVR-negative MCI and AD
subjects. By comparison, no corresponding reductions in
brain parenchyma volume were observed in the JVR-
positive MCI and AD subjects compared with the JVR-
positive controls.
Receiver operating curve analysis
The results of the univariate analysis revealed JVR to be
associated with a trend towards increased WB and GM
volumes in both the MCI and AD groups, something
that was not observed in the control group. In order to
confirm this finding we used PCA to orthogonalize/
combine these variables and used the resulting first prin-
cipal component to perform a ROC analysis, the results
of which are presented in Figure 1 and Table 4. From
this, it can be seen that the ROC results are strongly sig-
nificant for the MCI and AD groups, and appear to cor-
roborate the findings of the univariate analysis. While
the ROC analysis did not yield a significant result for the
control group, it was able to discriminate between the
JVR-positive and negative subjects in the other two
groups with reasonable accuracy (>70%). Indeed, for
the AD group, the ROC analysis achieved sensitivity
and specificity scores of 71.4% and 88.9%, respectively
(p = 0.007). As such, the results suggest that JVR was
associated with structural changes in the brain paren-
chyma in both the MCI and AD subjects.
Discussion
The results of the study do not support the hypothesis
that JVR is specifically associated with MCI and AD.
The incidence of JVR was very similar in both the
Table 3 MRI variables classified according to JVR status (i.e. positive or negative) for each disease group
JVR negative JVR positive Significance p value Cohen’s d
Controls, n (%) 5 (21.7) 13 (29.5) n.a. n.a.
Normalized WB volume, mean (SD) 1341.7 (44.6) 1342.3 (54.5) 0.924 0.013
Normalized GM volume, mean (SD) 719.7 (42.2) 731.3 (34.2) 0.633 0.326
Normalized WM volume, mean (SD) 622.0 (23.7) 611.0 (29.4) 0.443 0.396
CSF volume 364.1 (33.5) 390.7 (50.4) 0.336 0.566
MCI, n (%) 9 (39.1) 24 (54.5) n.a. n.a.
Normalized WB volume, mean (SD) 1274.9 (68.3) 1321.7 (55.8) 0.079 0.754
Normalized GM volume, mean (SD) 686.8 (49.3) 726.0 (37.7) 0.045 0.890
Normalized WM volume, mean (SD) 588.1 (32.8) 595.7 (35.3) 0.824 0.221
CSF volume 377.3 (54.2) 350.8 (61.7) 0.284 0.440
AD, n (%) 9 (39.1) 7 (15.9) n.a. n.a.
Normalized WB volume, mean (SD) 1267.8 (35.2) 1322.2 (54.7) 0.054 1.060
Normalized GM volume, mean (SD) 683.4 (26.6) 716.8 (42.9) 0.142 0.889
Normalized WM volume, mean (SD) 584.4 (30.4) 605.5 (26.2) 0.252 0.709
CSF volume 392.9 (75.1) 346.8 (66.2) 0.252 0.632
MCI and AD combined, n (%) 18 (78.3) 31 (70.5) n.a. n.a.
Normalized WB volume, mean (SD) 1271.4 (52.8) 1321.8 (54.7) 0.009 0.858
Normalized GM volume, mean (SD) 685.1 (38.4) 723.9 (38.4) 0.003 0.914
Normalized WM volume, mean (SD) 586.3 (30.8) 597.9 (3.34) 0.356 0.358
CSF volume 385.1 (64.0) 349.9 (61.6) 0.076 0.548
MCI Mild cognitive impairment, AD Alzheimer’s disease, JVR Jugular venous reflux, WB Whole brain, GM Gray matter, WM White matter, CSF Cerebrospinal fluid.
Volumes are expressed in millilitres.
n.a. not applicable, n Number, SD Standard deviation, % - Percentage.
p values determined by 2-tailed Mann Whitney U-test.
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AD group. Having said this, the results suggest that JVR
is associated with a rather unexpected phenomenon.
JVR appears to be associated with structural changes in
the brain parenchyma of patients with MCI and AD that
were not observed in the control group. This is highlighted
in the results presented in Table 3, which revealed a
marked difference in response to JVR between the controlsFigure 1 Receiver operating characteristic (ROC) curves for: (A) the co
using the first principal component of the normalized whole brain and graand the other two groups. Overall, the subjects with JVR
had greater WB and GM volumes, which was accompanied
by decreased CSF volume, compared with those without
JVR (Table 2). This effect was particularly marked in the
MCI and AD groups, whereas it was absent in the controls
(Table 3). As such, the observation that AD patients with
JVR exhibit larger WB volumes is a surprising finding, as
AD is normally characterized by advanced brain atrophy.ntrols; (B) the MCI subjects; (C) the AD patients. ROC undertaken
y matter volumes combined.
Table 4 Results of receiver operating curve (ROC) analysis of jugular venous reflux status using the first principal
component of the normalized whole brain and gray matter volumes combined
Group Area under
curve
True
positives
False
negatives
True
negatives
False
positives
Sensitivity Specificity Accuracy Significance
p value
Controls 0.538 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.401
MCI 0.713 19 5 5 4 79.2% 55.5% 72.7% 0.012
AD 0.794 5 2 8 1 71.4% 88.9% 81.3% 0.007
MCI Mild cognitive impairment, AD Alzheimer’s disease.
n.s. Not significant.
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and positive groups separately. In the JVR-negative subjects
there was a statistically significant reduction in global and
tissue specific brain parenchymal volumes in the AD and
MCI groups compared with the controls - a finding that is
consistent with the observations of many other researchers
[12-15,24]. However, no corresponding reduction was ob-
served in the JVR-positive group, implying that in some
way JVR inhibited brain volumetric loss in the AD and
MCI subjects. Compared with insufficient cerebral arterial
supply (arterial ischemia), cerebral venous drainage impair-
ment with venous hypertension causes more severe
vasogenic edema and brain–blood barrier damage [5-7].
Previous studies of JVR provide evidence that retrograde-
transmitted venous hypertension from JVR can reach the
cerebral venous system [10,11]. It is therefore possible that
JVR retrogradely transmits venous hypertension into the
brain, leading to increased permeability of the blood–
brain barrier (BBB), resulting in vasogenic edema, causing
the brain tissue to swell. Disruption of the BBB will allow
plasma molecules to pass into the brain, with the result
that an osmotic pressure gradient is established which will
contribute to edema formation. While it is not known if
this mechanism is at work, it is noticeable that JVR was
associated with a marked reduction in CSF volume in the
MCI and AD subjects, something that would be consist-
ent with an influx of CSF into the parenchymal tissue. Al-
ternatively, JVR might promote the retention of blood in
the cerebral veins [25] – something that might increase
the volume of the brain parenchyma.
The results of the ROC analysis demonstrate that it is
possible to discriminate between the JVR-positive and
negative MCI and AD subjects with reasonable accuracy
using just the MRI variables, normalized WB volume
and normalized GM volume, whereas this was not the
case in the control group. As such, this finding appears
to corroborate those of the univariate analysis. Further-
more, the ROC analysis suggests that a progressive effect
may be occurring, which is stronger in the AD group
(area under curve (AUC) = 0.794; p = 0.007) than in the
MCI group (AUC = 0.713; p = 0.012). While this finding
is difficult to interpret, it is known that MCI is fre-
quently a precursor to AD [26].While the exact physiological mechanisms behind our
intriguing observations are unclear, it is known that JVR
can induce hypertension in the dural sinuses [10,11] and
that this can alter intracranial CSF dynamics [27]. There-
fore, it may be that retrograde-transmitted venous pres-
sure associated with JVR inhibits CSF absorption into the
superior sagittal sinus [28]. Absorption of CSF into the
dural venous sinuses requires a pressure gradient of about
5–7 mmHg [29,30]. Therefore, an increase in venous pres-
sure of few mmHg due to occlusion of the venous drain-
age pathways [31], or reflux, will tend to inhibit the bulk
flow of CSF, as observed by Zamboni et al. [32]. If CSF
flow is inhibited, then this might result in increased bio-
chemical concentrations in the CSF. Overproduction of
Aβ is thought to damage WM in AD [33]. Given that pa-
tients with AD have been shown to exhibit 30% slower Aβ
clearance [1], it has been postulated [4] that accumulation
of Aβ in the CSF, arising from venous hypertension, may
precipitate the onset of AD. However, our results do not
support this conclusion. While JVR may be associated
with accumulation of Aβ in the CSF, our results do not in-
dicate that JVR precipitates the onset of AD. Indeed, the
majority of AD patients in our study were JVR-negative.
Having said this, the results suggest that JVR is having an
effect on the brain parenchyma of the MCI and AD pa-
tients, and the possibility that this might involve CSF
accumulation of Aβ cannot be excluded. Further inves-
tigations are therefore needed to elucidate the under-
lying neuropathological mechanisms associated with
our observations.
In this study we focused solely on JVR and ignored
other phenomena associated with constricted cerebral
venous outflow [34]. However, it may be that restricted
venous outflow, such as that associated with chronic
cerebrospinal venous insufficiency [35,36], might also be
influential. Studies of cerebral arteriovenous malforma-
tion have shown that the elevated venous pressure and
its insults to intracranial structures are more severe
when combined with obstruction in other venous out-
flow tracts [37,38]. Therefore it may be the case in JVR,
that retrogradely-transmitted venous pressure into cerebral
circulation needs additionally an obstruction of contralat-
eral venous outflow pathway to cause significant venous
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portant to remember that a diagnosis of ‘no-JVR’ does not
preclude the possibility that constricted cerebral venous
outflow might be present. Furthermore, engorged veins are
frequently observed upstream of stenotic lesions [39] and
it may be that muscular compression of these veins also
contributes to JVR.
Although it yielded novel and interesting findings, it
should be noted that our study was limited in its scope,
having a relatively small sample size. In particular, the
AD group contained fewer JVR-positive individuals com-
pared with the other two groups. Also, because of the
limited numbers involved, we restricted ourselves to a
simple positive/negative JVR classification and did not
distinguish between bilateral, left and right-sided JVR. It
is therefore not known the extent to which left and right
sidedness in JVR influences brain atrophy and further
work will be required to evaluate this. Furthermore, there
are other venous abnormalities associated with aging and
other neurological disorders which we were not able to as-
sess [9,27,40]. Nevertheless, our findings are novel and
suggest that cerebral venous drainage impairment may in-
fluence the neuropsychology of AD. Further studies, par-
ticularly longitudinal studies, are therefore needed to
build on our initial findings.
Conclusions
JVR is associated with intracranial structural changes in
MCI and AD patients, which result in increased WB and
GM volumes. Although the neuropathology associated
with this unexpected and counterintuitive finding re-
quires further investigation, it may be that JVR retro-
gradely transmits venous hypertension into the brain,
and that this leads to the brain tissues swelling due to
vasogenic edema.
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